EU/3/03/171: Orphan designation for the treatment of ovarian cancer

trabectedin

Table of contents

Overview

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in October 2019 at the end of the 10-year period of market exclusivity.

On 17 October 2003, orphan designation (EU/3/03/171) was granted by the European Commission to PharmaMar S.A., Spain, for trabectedin for the treatment of ovarian cancer.

Ecteinascidin 743 in treatment of ovarian cancer has been authorised in the EU as Yondelis since 28 October 2009.

Key facts

Active substance
trabectedin
Medicine name
Yondelis
Intended use
Treatment of ovarian cancer
Orphan designation status
Expired
EU designation number
EU/3/03/171
Date of designation
17/10/2003
Sponsor
PharmaMar S.A.
Polígono Industrial La Mina
Av. de los Reyes 1
28770 Colmenar Viejo
Madrid
Spain
Telephone: (34-91) 846 60 00
Telefax: (34-91) 823 45 03
E-mail: pharmamar@pharmamar.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating